Features of the Pathogenesis of Late-Life Depression
https://doi.org/10.30629/2618-6667-2020-18-1-41-49
Abstract
Objective: to present a review of domestic and foreign modern studies highlighting the features of the pathogenesis of depressive disorders in late age. Material and method: using the keywords «depression», «late age», «pathogenesis», scientific articles were searched in the MEDLINE/PubMed databases for the period 2000–2020. Conclusion: Despite the large number of hypotheses regarding the pathogenesis of depression, they are not mutually exclusive, but rather complementary, which reflects the systemic multifactorial nature of depressive disorders, primarily late-age depression. However, many of these hypotheses are closely related. It is likely to suggest that late-life depression is a heterogeneous clinical syndrome with multiple etiologies of depressive disorders, and the involvement of various pathogenetic mechanisms. The study of the pathogenesis of depressive disorders in late life reveals important and promising areas for further research in order to develop personalized therapeutic approaches and identify predictors of therapeutic response. Selection of adequate psychopharmacotherapy in this age group is especially relevant in relation to often recurrent and therapy-resistant depressions, which are factors of unfavorable prognosis of the disease as a whole.
About the Author
T. P. Safarova
Mental Health Research Centre
Russian Federation
Russian Federation
Tatyana P. Safarova - PhD, MD, Cand. of Sci. (Med.), Geriatric Psychiatry Department, FSBSI «Mental Health Research Centre».
Moscow.
References
1. Mosolov SN. Modern biological hypotheses of recurrent depression (review). Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2012;112(11):29-40. (In Russ).
2. Kasper S, Laigle L, Bayl OF. Superior antidepressant efficacy of agomelatine vs sertraline: a randomised, double-blind study. Eur. Neuropsychopharmacol. 2008;18(4):336.
3. Koenigsberg HW, Teicher MH, Mitropoulou V, Navalta C, New AS, Trestman R, Siever LJ. 24-h monitoring of plasma norepinephrine, MHPG, cortisol, growth hormone and prolactin in depression. J. Psychiat. Res. 2004;(38):503-511.
4. Lam RW. Addressing circadian rhythm disturbances in depressed patients. J. Psychopharmacol. 2008;22(7):13-8. DOI:10.1177/0269881108092591.
5. Mendlewicz J. Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. World J. Biol. Psychiat. 2009;10(4):269-75. DOI :10.3109/15622970802503086.
6. Mendlewicz J. Addressing circadian rhythm disturbances in depressed patients. J. Psychopharmacol. 2008;22:(7):13-18. DOI:10.1177/0269881108092591.
7. Buysse DJ. Insomnia, depression, and aging: Assessing sleep and mood interactions in older adults. Geriatrics. 2004;59(2):47-51.
8. Foley D, Ancoli-Israel S, Britz P, Walsh J. National Sleep Foundation: Sleep in America Poll: 2002. J. Psychosom. Res. 2004;56(5):497-502.
9. Costa I, Carvalho H, Fernandes L. Aging, circadian rhythms and depressive disorders: a review. Am. J. Neurodegener. Dis. 2013;2(4):228-246.
10. Ivanov SV. Valdoxan (agomelatine) in the treatment of moderate and severe depressions of a nonpsychotic level in outpatient and hospital practice (results of the Russian multicenter study CHRONOS). Psychiatry and psychopharmacotherapy. 2009;(6):14- 17. (In Russ.).
11. Kalyn YB, Safarova TP, Yakovleva OB, Sheshenin VS, Kornilov VV, Shipilova ES, Gavrilova SI. Experience with agomelatine (valdoxane) in a gerontopsychiatric hospital for the treatment of elderly patients with depression. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2015;115(11):55-62. (In Russ.).
12. Hammen C. Stress and depression. Ann. Rev. Clin. Psychol. 2005;(1):293-319. DOI:10.1146/annurev.clinpsy.1.102803.143938
13. Neznanov NG, Mazo GE, Kozlova SN. Pathophysiological aspects of formation of depression in the book Smulevich AB. Depression in mental and somatic diseases. 4th edition. M. 2015;78-105. (In Russ.).
14. Neznanov NG., Kruglov LS. The background of the biopsychosocial reasons of psychopathological symptoms peculiarities in old age patients. V.M. Bekhterev review of psychiatry and medical psychology. 2015;(4):3-9. (In Russ.).
15. Kekelidze ZI. Guide to emergency psychiatry. 2nd ed. M., 2011;(1):280-300. (In Russ.).
16. Anderson P. Bereavement Associated With Early Mortality Risk. Lancet. 2007;(370):1829-1839.
17. Murphy E. Social origins of depression in old age. British Journal of Psychiatry. 1982;141:135-142. DOI:10.1192/bjp.141.2.135.
18. Kornilov VV. Pathological reaction of grief at a late age with the outcome in affective disorder. Psychiatry. 2017;2(74):10-23 (In Russ.).
19. Kornilov VV. The role of the pathological reaction of grief in the development of late-stage dementia. Psychiatry. 2018;1(77):5-15. (In Russ.).
20. Lucassen PJ, Stumpel MW, Wang Q, Aronica E. Decreased numbers of progenitor cells but no response to antidepressant drugs in the hippocampus of elderly depressed patients. Neuropharmacology. 2010;58:940- 949. DOI:10.1016/j.neuropharm.2010.01.012
21. Zozulya SA, Oleichik IV, Androsova LV, Otman IN, Sarmanova ZV, Stolyarov SA, Bizyaeva AS, Unilainen OA, Klyushnik TP. Monitoring the course of endogenous psychosis by immunological parameters. J. Mental Health. 2017;(1):11-18. (In Russ.).
22. Klyushnik TP, Zozulya SA, Oleichik IV. Markers of immune system activation in monitoring the course of endogenous mental diseases. V kn. Biologicheskie marker shizofrenii: poisk i klinicheskoe primenenie pod redaktsiei akademika RAN NA Bokhana, professor SA Ivanovoi. Novosibirsk. Izdatel'stvo SO RAN. 2017;34-46. (In Russ.).
23. Armao D, Kornfeld M, Estrada EY, Grossetete M, Rosenberg GA. Neutral proteases and disruption of the blood-brain barrier in rat. Brain Research. 1997;767(2):259-264.
24. Klyushnik TP, Lideman PP. Autoimmune mechanisms in the Genesis of disorders of the nervous system. Vestnik Rossijskoj akademii med. nauk. 2001;(7):32- 34. (In Russ.).
25. Maes M, Kubera M, Mihailova I. Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J. Affect. Disord. 2013;149(1- 3):23-29. DOI:10.1016/j.jad.2012.06.039.
26. Klyushnik TP, Siryachenko TM, Sarmanova ZV. Immunological reactions in various forms of mental pathology. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2009;109(4):55-58. (In Russ.).
27. Klyushnik TP, Androsova LV, Mikhailova NM, Kolykhalov IV, Zozulya SA, Dupin AM. Systemic inflammatory markers with age-related cognitive decline and Alzheimer's disease. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2017;117(7):74-79. (In Russ.).
28. Halaris A, Leonard BE (eds.): Mod Trends Pharmacopsychiatry. Neuroprogression in Psychiatric Disorders. Basel, Karger, 2017;(31):56-66. DOI:10.1159/000470807.
29. Alexopoulos GS., Morimoto SS. The inflammation hypothesis in geriatric depression. Int. J. Geriatr. Psychiatry. 2011;(26):1109-1118. DOI:10.1002/gps.2672.
30. Alexopoulos GS. Mechanisms and treatment of late- life depression. Translational Psychiatry. 2019;(9):1- 16. DOI:10.1038/s41398-019-0514-6.58.
31. Benarroch EE. Brain glucose transporters: implications for neurologic diseases. Neurology. 2014;15:1374- 1379. DOI:10.1212/wnl.0000000000000328.
32. Mergenthaler P, Lindauer L, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36:587-597.
33. Wang SJ, Tu PC, Hsieh JC: Prefrontal glucose metabolism in medication-resistant major depression. Br. J. Psychiatry. 2015;206(4):316-323. DOI:10.1192/bjp.bp.113.140434.
34. Myint AM. Kynurenines: From the perspective of major psychiatric disorders. FEBS J. 2012;(279):1375- 1385. DOI:10.1111/j.1742-4658.2012.08551.
35. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio 0, Belzung C, Hen R: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003(301):805-809.
36. Kheirbek MA, Hen R. Add neurons, subtract anxiety. Article in Scientific American. 2014.311(1):62-67.
37. Miller BR, Hen R. The current state of the neurogenic theory of depression and anxiety. Curr. Opin. Neurobiol. 2015;(30):51-58. DOI:10.1016/j.conb.2014.08.012.
38. Spalding KL, Bergmann O, Alkass K, Bernard S, Saleh- pour M, Huttner HB, Bostrom E, Westerlund I, Vial C, Buchholz BA, Possnert G, Mash DC, Druid H, Frisen J. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013;(156):1219-1227. DOI:10.1016/j.cell.2013.05.002
39. Bergmann O, Spalding KL, Frisen J: Adult neurogenesis in humans. Cold Spring Harb. Perspect. Biol. 2015. (7):018994. DOI:10.1101/cshperspect.a018994.
40. Fossati P, Radtchenko A, Boyer P. Neuroplasticity: from MRI to depressive symptoms. Eur. Neuropsychopharmacol. 2004:14(5):503-510. DOI:10.1016/j.euroneuro.2004.09.001.
41. Sheline YI, Gado MH, Kraemer HC. Untreated de-pression and hippocampal volume loss. American Journal of Psychiatry. 2003;160(8):1516-1518. DOI.org/10.1176/appi.ajp.160.8.1516
42. Kays JL, Hurley RA, Taber KH. The dynamic Brain: Neyroplasticity and Mental Health. The Journal of Neuropsychiatry and Clinical Neurosciences. 2012;24(2):118-124.
43. Bennett MR. The prefrontal-limbic network in de-pression: a core pathology of synapse regression. Progress Neurobiology. 2011;93(4):457-467. DOI.org/10.1016/j.pneurobio.2011.01.001.
44. Hanson ND, Owens MJ, Nemeroff CB. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology. 2011;(36):2589-260230. https://DOI.org/10.1038/npp.2011.220.
45. Aftanas LI. Depression and neurodegeneration: new strategies for diagnosis and therapy. Nauka iz pervyh ruk. 2017;(1):41-49. (In Russ.).
46. Geerlings MI, Schoevers RA, Beckman AT Depression and risk of cognitive decline and Alzheimer's disease. Results of two prospective community based studies in the Netherlands. Br. J. Psychiatry. 2000;(176):568-575.
47. Visser PJ, Verhey FR, Ponds RW. Distinction between preclinical Alzheimer's disease and depression. J. Am. Geriatr. Soc. 2000;(48):479-484.
48. Modrego PJ, Fernandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of the Alzheimer type. Arch. Neurol. 2004;(61):1290-1293.
49. Benoit M, Berrut G, Doussaint S. Apathy and depression in mild Alzheimer's disease: a cross-sectional study using diagnostic criteria. J. Alzheimers Dis. 2012;31(2):325-334. DOI:10.3233/JAD-2012-112003.
50. Harwood DG, Barker WW, Ownby RL, Duara R. Association between premorbid history of depression and current depression in Alzheimer's disease. J. Geriatr. Psychiatry Neurol. 1999;12(2):72-75. DOI:10.1177/089198879901200206.
51. Green RC, Cupples LA, Kurz A. Depression as a risk factor for Alzheimer's disease: the MIRAGE study. Arch. Neurol. 2003;60(5):753-759. DOI.org/10.1001/archneur.60.5.753.
52. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum. Mol. Genetics. 2010;19(R1):R12-20. DOI:10.1093/hmg/ddq160.
53. Cortes F, Portet F, Touchon J, Vellas B. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? J. Nutr. Health Aging. 2007;11(4):330-337.
54. Ernst A, Frisen J. Adult neurogenesis in humans — common and unique traits in mammals. PLoS Biol. 2015;13:el002045. DOI:10.1371/journal.pbio.1002045.
55. Chung YC, Kim SR, Jin BK. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of PD disease. J. Immunol. 2010;(185):1230-1237.
56. Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spen¬cer B, Rockenstein E, May V, Winkler J, Masliah E. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of a-synucleinopathy. Exp. Neurol. 2012;(234):405-416.
57. Handa J, Sekiguchi M, Krupkova O, Konno S. The effect of serotonin-noradrenaline reuptake inhibitor duloxetine on the intervertebral disk-related radiculopathy in rats Eur. Spine J. 2016;25(3):877-887. DOI:10.1007/s00586-015-4239-9.
58. Kruglov LS, Meshchanin IA. late-age depression in patients with cerebral vascular disorders: features of the clinical picture and therapeutic dynamics. V.M. Bekhterev review of psychiatry and medical psychology. 2011(1):18-22. (In Russ.).
59. Lyness JM. The cerebrovascular model of depression in late life. CNS Spectr. 2002;7(10):712-715.
60. Steffens DC, Bosworth HB, Provenzale JM, MacFall JR. Subcortical white matter lesions and functional impairment in geriatric depression. Depress Anxiety. 2002;15(1):23-28. DOI:10.1002/da.1081.
61. Van Straaten ICW, Scheltens P. Imaging abnormalities and depression in the elderly. Medicographia. 2003;(25):68-71.
62. Taylor WD, MacFall JR, Payne ME, McQuoid DR, Stef-fens DC, Provenzale JM, Krishnan KR. Greater MRI lesion volumes in elderly depressed subjects than in control subjects. Psychiatry Res. 2005;(139):1-7.
63. Jacobsen JSt, Reinhart P, Pangalos MN. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in alzheimer's disease. The Journal of the American Society for Experimental NeuroTherapeutics. 2005;(2):612-626. DOI:10.1602/neurorx.2.4.612.
64. Folstein M, Liu T, Peter I. The Homocysteine Hypothesis of Depression. Am. J. Psychiatry. 2007;(164):861- 886.
65. Yakovleva OB, Safarova TP, Miroshnichenko II, Platova AI. Homocysteine in later age depressions. Psychiatry. 2015;(2):29-36. (In Russ.).
66. Miroshnichenko II, Platova AI, Safarova TP, Yakovleva OB. Quantitative determination of homocysteine by tandem chromatography-mass spectrometry with chemical ionization. Biomedical chemistry. 2014;60(2):235-245. (In Russ.).
67. Woods AG, Wormwood KL, Iosifescu DV, Murrough J, Darie CC. Protein Biomarkers in Major Depressive Disorder: An Update. Advancements of Mass Spectrometry in Biomedical Research. Advances in Experimental Medicine and Biology. 2019;(1140):585-600. DOI.org/10.1007/978-3-030-15950-4_35.
68. Masse-Sibille C, Djamila B, Julie G, Emmanuel H, Pierre V, Gilles Ch. Predictors of Response and Remission to Antidepressants in Geriatric Depression: A Systematic Review. J. Geriatric Psychiatry and Neurology. 2018,'31(6)283-302. DOI:10.1177/0891988718807099.
Review
For citations:
Safarova T.P. Features of the Pathogenesis of Late-Life Depression. Psychiatry (Moscow) (Psikhiatriya). 2020;18(1):41-49. (In Russ.) https://doi.org/10.30629/2618-6667-2020-18-1-41-49
Views:
927
Email this article 
